89bio, Inc.

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersSan Francisco, California¹
• Incorporated inDE²
• Business address655 Montgomery Street, Suite 1500, San Francisco, Ca 94111²
• Filer categoryLarge accelerated filer²

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (“FGF21”), is currently being developed for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), previously known as nonalcoholic steatohepatitis, and for the treatment of severe hypertriglyceridemia (“SHTG”).³ From its latest annual report

Corporate structure

89bio, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What 89bio, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

Our corporate headquarters is located in San Francisco, California, and consists of 17,616 square feet of office space under a lease that expires in March 2027. We believe that our current space is adequate for our needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.

Item 2 of the 10-K filed Feb 27, 2025.³

Leadership

Who has led 89bio, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRohan Palekar Nov 8, 2019 to now¹²
• Chief financial officerRyan Martins Nov 8, 2019 to now¹³
• Chief operating officerFrancis Willard Sarena Aug 7, 2024 to now¹⁴
• Chief operating officerRam Waisbourd Mar 16, 2020 to Nov 18, 2020¹⁵

Timeline

1. Oct 30, 20258-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer³¹
2. Sep 18, 20258-K Entered a material agreement; Other events³²
3. Aug 7, 20258-K Results of operations³³
4. May 30, 20258-K Shareholder vote³⁴
5. May 1, 20258-K Results of operations³⁵
6. Apr 9, 20258-K Regulation FD disclosure³⁶
7. Feb 27, 20258-K Results of operations³⁷
8. Feb 4, 20258-K Executive or director change³⁸
9. Jan 29, 20258-K Entered a material agreement³⁹
10. Jan 13, 20258-K Results of operations; Other events⁴⁰
11. Dec 16, 20248-K Executive or director change⁴¹
12. Nov 14, 20248-K Entered a material agreement⁴²
13. Nov 8, 2019New chief executive Rohan Palekar becomes CEO¹²

Calendar

When it reported results

1. Aug 7, 2025Reported quarterly or annual results³³
2. May 1, 2025Reported quarterly or annual results³⁵
3. Feb 27, 2025Reported quarterly or annual results³⁷
4. Jan 13, 2025Reported quarterly or annual results⁴⁰
5. Nov 7, 2024Reported quarterly or annual results⁴³
6. Aug 5, 2024Reported quarterly or annual results⁴⁴
7. May 9, 2024Reported quarterly or annual results⁴⁵
8. Feb 29, 2024Reported quarterly or annual results⁴⁶

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

380 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 51 major events, 185 insider forms, 64 large holders, 64 other. The latest 20:

1. Feb 13, 2026SCHEDULE 13G/A EDGAR
2. Nov 19, 2025EFFECT EDGAR
3. Nov 14, 2025SCHEDULE 13G/A EDGAR
4. Nov 14, 2025SCHEDULE 13G EDGAR
5. Nov 13, 2025SCHEDULE 13G/A EDGAR
6. Nov 10, 202515-12G EDGAR
7. Nov 3, 2025SCHEDULE 13D/A EDGAR
8. Nov 3, 20254 EDGAR
9. Oct 31, 2025SCHEDULE 13D/A EDGAR
10. Oct 30, 20254 EDGAR
11. Oct 30, 20254 EDGAR
12. Oct 30, 20254 EDGAR
13. Oct 30, 20254 EDGAR
14. Oct 30, 20254 EDGAR
15. Oct 30, 20254 EDGAR
16. Oct 30, 20254 EDGAR
17. Oct 30, 20254 EDGAR
18. Oct 30, 20254 EDGAR
19. Oct 30, 20254 EDGAR
20. Oct 30, 20254 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

41 open-market trades by officers, directors and large owners since October 2021: 16 buys and 25 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Deep Track Capital, LPSCHEDULE 13G/A, 6 filings Jul 6, 2022 to Feb 13, 2026⁴⁷
• Pentwater Capital Management LPSCHEDULE 13G, 1 filing Nov 14, 2025⁴⁸
• MONTANOVA CAPITAL, LLCSCHEDULE 13G/A, 6 filings Oct 30, 2023 to Nov 13, 2025⁴⁹
• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D/A, 11 filings Jul 6, 2022 to Nov 3, 2025⁵⁰
• Adage Capital Management, L.P.SCHEDULE 13D/A, 2 filings Oct 3, 2025 to Oct 31, 2025⁵¹
• Janus Henderson Group Ltd.SCHEDULE 13G/A, 9 filings Feb 14, 2023 to Oct 7, 2025⁵²
• VANGUARD GROUP INCSCHEDULE 13G, 1 filing Jul 29, 2025⁵³
• RTW INVESTMENTS, LPSCHEDULE 13G/A, 3 filings Feb 14, 2024 to May 15, 2025⁵⁴
• BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 5 filings Jul 11, 2022 to Feb 14, 2025⁵⁵
• BlackRockSC 13G/A, 3 filings Jan 29, 2024 to Nov 8, 2024⁵⁶
• State Street CorporationSC 13G/A, 2 filings Jan 24, 2024 to Oct 17, 2024⁵⁷
• Cormorant Asset Management, LPSC 13G/A, 2 filings Dec 29, 2022 to Feb 14, 2024⁵⁸
• ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 3 filings Aug 12, 2022 to Feb 7, 2024⁵⁹
• ORBIMED ADVISORS LLCSC 13D/A, 3 filings Jul 5, 2022 to Mar 24, 2023⁶⁰
• GREAT POINT PARTNERS LLCSC 13G/A, 2 filings Jul 8, 2022 to Feb 14, 2023⁶¹
• Longitude Capital Partners III, LLCSC 13D/A, 2 filings Feb 7, 2022 to Feb 14, 2023⁶²
• Wellington Management CompanySC 13G/A, 2 filings Jan 10, 2022 to Jun 10, 2022⁶³
• Ran NussbaumSC 13G/A, 1 filing Feb 14, 2022⁶⁴

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How 89bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGAR89bio, Inc.¹
• CIK0001785173
• Employer ID (EIN)36-4946844³
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address655 Montgomery Street, Suite 1500, San Francisco, CA 94111¹
• Phone(415) 432-9270¹
• Shares outstanding148,308,250 as of Jul 31, 2025¹⁰
• Public float$722.4M as of Jun 28, 2024³
• AuditorKPMG LLP, San Francisco, California, USA PCAOB ID 185; it also attests to the company’s internal control over financial reporting³
• On EDGAR sinceAug 16, 2019¹
• Filings559 in all: 4 (241), 8-K (71), SC 13G/A (23), 3 (20), SC 13D/A (20), 10-Q (18), CORRESP (14), SC 13G (13)¹
  All 50 form types

  SCHEDULE 13G/A (12), 144 (11), 424B5 (11), S-8 (7), S-8 POS (7), UPLOAD (7), 10-K (6), DEF 14A (6), DEFA14A (6), EFFECT (6), SCHEDULE 13D/A (4), 424B4 (3), 8-K/A (3), ARS (3), DRS (3), S-1 (3), SC 13D (3), SC14D9C (3), SCHEDULE 13G (3), FWP (2), POSASR (2), S-1MEF (2), S-3 (2), S-3ASR (2), SC 14D9/A (2), SC TO-C (2), SC TO-T/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 8-A12B (1), CERT (1), DRS/A (1), DRSLTR (1), NT 10-K (1), POS AM (1), PRE 14A (1), S-1/A (1), S-3/A (1), SC 14D9 (1), SC TO-T (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (10-K) Feb 27, 2025
  Quarterly report (10-Q) Aug 8, 2025
  Proxy statement (DEF 14A) Apr 15, 2025
  Latest 8-K (8-K) Oct 30, 2025

Securities registered for trading

From the cover page of the 10-K filed Feb 27, 2025 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks 89bio, Inc. names in Item 1A of its 10-K filed Feb 27, 2025: 56 risks under these headings, as written.³

• Risks Related to Our Business and Industry
• We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred net losses since our inception, we expect to incur significant and increasing operating losses and we may never be profitable. Our stock is a highly speculative investment.
• Our business depends on the success of pegozafermin, our only product candidate under clinical development, which has not completed a pivotal trial. If we are unable to obtain regulatory approval for and successfully commercialize pegozafermin or other future product candidates, or we experience significant delays in doing so, our business will be materially harmed.
• Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and the results of prior preclinical or clinical trials are not necessarily predictive of our future results.
• We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of pegozafermin or develop new product candidates.
• If we experience delays in clinical testing, our commercial prospects will be adversely affected, our costs may increase and our business may be harmed.
• If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• We have relied on, and expect to continue to rely on, third-party manufacturers and vendors to produce and release pegozafermin or any future product candidates. Any failure by a third-party to produce and release acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products.
• Pegozafermin and any future product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or limit the commercial profile of an approved label.
• We are developing pegozafermin for the treatment of MASH and SHTG. The requirements for approval of pegozafermin by the FDA and comparable foreign regulatory authorities may be difficult to predict and may change over time, which makes it difficult to predict the timing and costs of the clinical development.
• Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing FGF product candidates, which could adversely affect our stock price, our ability to attract additional capital and our development program.
• Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

Legal proceedings

We are currently not a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.

The opening of Item 3, Legal Proceedings.³